ReviewCureus2025
Histopathological Subtypes of Cutaneous Melanoma: Prognostic and Molecular Implications.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Absence of Ochre Fluorescence in Acral Melanoma Under Ultraviolet Dermoscopy.International journal of dermatology · 2026Article
- Modeling rare melanoma subtypes: mechanisms, microenvironments and translational opportunities.Frontiers in oncology · 2026Review
- Artificial Intelligence and New Technologies in Melanoma Diagnosis: A Narrative Review.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous melanoma is a biologically diverse and clinically aggressive malignancy with distinct histopathological subtypes that significantly influence its diagnosis, prognosis, and management. This comprehensive review explores the major melanoma subtypes, superficial spreading, nodular, lentigo maligna, acral lentiginous, and desmoplastic melanoma, along with rarer variants such as spitzoid, nevoid, and mucosal melanomas. Each subtype exhibits unique morphological characteristics, growth patterns, anatomical distribution, and molecular profiles, including variations in key mutations such as B-Raf proto-oncogene, serine/threonine kinase (BRAF), KIT proto-oncogene receptor tyrosine kinase (KIT), Neuroblastoma RAS viral oncogene homolog (NRAS), and Neurofibromin 1 (NF1). While histologic subtype is not incorporated into formal staging systems, it frequently correlates with tumor behavior and patient outcomes, guiding surgical planning and adjuvant therapy decisions. Advances in immunohistochemistry, molecular diagnostics, and genomic profiling have refined melanoma classification and opened new avenues for targeted and immune-based therapies. However, diagnostic challenges persist due to overlapping features and under-characterization of rare variants. This review underscores the need for a multimodal approach that integrates histopathologic, molecular, and clinical data to achieve precise classification and optimize patient care in the era of personalized oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.